PBS lists medications to reduce severity of COVID-19 19 July 2022 Medications that reduce the severity of COVID-19 are now available on the Pharmaceutical Benefits Scheme (PBS). Oral anti-viral medications, Paxlovid and Lagevrio, can now be prescribed by doctors or authorised nurse practitioners to people living with any type of diabetes who use medication to manage their condition and have another condition. Other conditions include heart or kidney disease or obesity. People living in residential aged care and all people aged 70 and over are also eligible even if they have no risk factors. The medications can be prescribed for: People 50 years of age or older, with two additional risk factors for developing severe COVID-19People 30 years of age or older identifying as Aboriginal or Torres Strait Islander, with two additional risk factors for developing severe diseasePeople 18 years of age or older, who are moderately to severely immunocompromised. The medicines must be started as soon as possible after a diagnosis of COVID-19. If you have developed COVID-19 please speak to your health team about accessing these medicines immediately. It is important to note anti-viral medicines are not intended to be used as substitutes for getting vaccinated against COVID-19. Diabetes Australia continues to recommend people get vaccinated and boosted in line with the latest advice from the Australian Technical Advisory Group on Immunisation.
Media releases 18 November 2026 Foundayo approval a welcome addition to GLP-1 treatment options Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a new oral GLP-1 receptor agonist for the management of type 2 diabetes and chronic weight management in eligible adults. Continue Reading
Media releases 6 November 2026 Diabetes Australia welcomes new oral GLP-1 treatment option for Australians Diabetes Australia welcomes the Therapeutic Goods Administration’s (TGA) recent approval of a new oral formulation of Wegovy (semaglutide) as a step forward in the treatment of obesity and related chronic conditions. Continue Reading
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading